Image: ModernaTX, Inc., the primary operating subsidiary and official web domain of Moderna, Inc.

A new mRNA influenza vaccine from Moderna, approved by the U.S. Food and Drug Administration (FDA) on August 5, has already been linked to 78 reports of adverse events in a federal safety monitoring system.

MFLUSIVA is reportedly a vaccine for active immunization against influenza caused by virus subtypes A and B contained in the vaccine.

But does the vaccine present a greater threat than the influenza it aims to prevent? Reports filed in the Vaccine Adverse Event Reporting System (VAERS) through late October document instances of sudden mobility loss, partial vision impairment, cardiac arrhythmia, syncope, and hospitalization.

A recent Focal Points report highlighted several of these concerning entries from VAERS, which were also shared on X by Nicholas Hulscher, an Epidemiologist and Administrator at the McCullough Foundation.

 

The Gateway Pundit spoke to Hulscher, author of the report and creator of the video. He quickly pointed out that “VAERS is widely understood to capture only a fraction of actual incidents,” referencing a Harvard-Lazarus study which estimated under one percent of incidents are actually reported.

“This underreporting,” he argued, “makes our foundation’s own peer-reviewed reanalysis of FDA clinical trial data all the more critical—it indicated the vaccine carries a risk of severe systemic reactions six times higher than that of conventional influenza vaccines.”

“In our study,” Hulscher stated, “risk-benefit projections suggested that for every hospitalization for influenza prevented by the mRNA vaccine relative to standard options, there were an estimated 3,798 adverse reactions, 278 severe events preventing normal activity, and two excess deaths from unexplained causes.”

According to him, these revelations stand in stark contrast to any initial assurances of safety and efficacy, raising fundamental questions about regulatory oversight and the adequacy of current pharmacovigilance systems in capturing true risk profiles for novel medical interventions.

“Given these preliminary findings,” Hulscher said, “The McCullough Foundation maintains its position that MFLUSIVA’s risk profile justifies its removal from the market.”

 

The post Moderna’s mRNA Flu Shot Linked to Surge in Severe Adverse Events, VAERS Data Shows appeared first on The Gateway Pundit.